Barclays initiated coverage of Amneal Pharmaceuticals (AMRX) with an Overweight rating and $15 price target The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying investor sentiment is improving as companies shift focus to innovation, margin expansion and de-leveraging. The group’s pricing headwinds are easing while debt leverage is coming down, the analyst tells investors in a research note. Barclays sees “plenty of opportunity” as the sector “remains in a transition phase.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals announces results from Phase 4 ELEVATE-PD
- Amneal receives U.S. FDA approval for albuterol sulfate inhalation aerosol
- Closing Bell Movers: MongoDB jumps 22% on earnings beat and raise
- Amneal announces FDA approval of cyclosporine ophthalmic emulsion 0.05%
- Amneal Pharmaceuticals announces FDA approval for iohexol injection